Barcelona, June 10th, 2022. In an invited Comment article recently published online first in The Lancet Oncology (1) , co-authors Elena…
featured news home
For the first time in the context of brain metastasis, VHIO-led research has evidenced the striking preclinical efficacy of a…
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and overall…
VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC inhibitor Omomyc effectively halts disease progression in metastatic…
HER2DX is the world’s first diagnostic test formulated specifically for HER2-positive (HER2+) breast cancer. HER2DX analyzes RNA on 27 genes…
High-throughput RNA sequencing studies have led to the identification of several long noncoding RNAs (lncRNAs), but without apparent protein-coding roles….
In her latest ESMO perspectives On target column entitled Food for thought: dietary effects on tumor metabolism & progression, VHIO’s Elena Garralda, Principal…
The Center of Excellence Severo Ochoa Award, granted within the subprogram of the Spanish Institutional Strengthening of the State Plan…
Officially launching tomorrow, Thursday 11 November, the next 3-year World Cancer Day (WCD) global campaign (2022-2024) is themed Close the…
2020 was a year of darkness as the COVID-19 pandemic wreaked its havoc globally. In its waves, it ravaged human…
